Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive Transfer of pp65-specific T Cells for Refractory CMV in HCT Recipients
NCT02346617Phase 2Withdrawn
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytomegalovirus pp65-specific cytotoxic t lymphocytes in cytomegalovirus infection (CMV). Primary endpoint: Level of enriched IFN-γ+ T-cells upon pp65 stimulation at 2 weeks. Planned start Jan 2022; status: withdrawn.
02
Drugs
cytomegalovirus pp65-specific cytotoxic t lymphocytes
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT02346617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02346617.